Skip to navigation Skip to content

Clinical Trial: Fingolimod

Share

Details
Type of MS: RRMS|SPMS
Treatment mode of action: To affect immune function
Number of Subjects: 3600
Medication: Fingolimod
Location: Mississippi
Institutions:

Multicenter, nationwide

Contact Information
Precise Research Centers
601-420-5810

Funding:

Novartis

Description

The purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with fingolimod or receiving another disease-modifying therapy, is to further explore the incidence of selected safety- related outcomes and to further monitor the overall safety profile of fingolimod under conditions of routine medical practice.

Share